Acute graft-versus-host disease (GVHD) following allogeneic stem cell transplantation has an adverse prognosis despite novel approaches with respect to both conditioning regimens and immunosuppression. Methylprednisolone (MP) 2 mg/kg body weight is generally used as an initial treatment; however, achievement of durable response to steroids widely varies with both the extent of human leukocyte antigen (HLA) disparity between donor and recipient and disease severity. [1] [2] [3] Failure of adequate response to MP represents refractory GVHD that is difficult to manage. Numerous approaches and agents have, often retrospectively, been evaluated. Besides significant escalation in steroid doses and some approaches using extracorporeal photopheresis mainly monoclonal antibodies (or equivalent constructs) have attracted special attention. 4, 5 Response to second-line treatment is often of transient nature and due to either secondary complications of intensified immunosuppression or progressing GVHD mortality remains discouragingly high. Our experience with monoclonal antibody directed against CD3 (OKT3 muromonab) as second-line and subsequent treatment in refractory GVHD 6 provided basis for a prospective, randomized trial in patients with steroid-resistant acute GVHD following transplantation of allogeneic hematopoietic cells. The study was approved by the Institutional Review Boards of all participating centers.
Patients with acute GVHD of grades II-IV developing until day 100 after transplantation were eligible to undergo randomization to either monoclonal antibody OKT3 (Orthoclone, Janssen-CILAG, Neuss, Germany) 5 mg intravenously once daily plus MP 10 mg/kg BW (HD-MP) versus HD-MP alone. Concomitant immunosuppression was to be continued. Primary end point was a trend for better response of acute GVHD at study day 100. Secondary end points included survival at 1 year after allogeneic hematopoietic cell transplantation, incidence of infectious complications and side effects of treatment. For both groups, reduction of steroids was scheduled for the first 8 days and then subject to decision of the local investigator. Assessment of overall severity of GVHD was performed on the day of registration and then daily; on the day of randomization and then daily until day 10 and on days 30 and 100 after the first dose of study drug, and 1 year from transplantation if a patient was alive. The survival analysis was performed on all patients who had received at least one dose of study medication. Response was evaluated on an intent-to-treat basis, thus excluding subjects requiring third-line therapy before study day 100. Data were prospectively registered and analyzed. Kaplan-Meier analysis was used to analyze survival, and differences in (event-free) survival between treatment subgroups were compared with the use of the log-rank test. Proportions in the study subgroups were compared with the use of the w 2 -test or Fisher's exact test (categorical variables). Mann-Whitney U-test and Student's t-test were applied as appropriate to test for group differences of ordinal or continuous variables. Po0.05 was considered to indicate statistical significance. Binary logistic regression analysis was used to assess the effect of age, HLA disparity, sex mismatch, onset of any infectious complications, initiation of third-line treatment and treatment modality (for example, MP alone vs OKT3 and HD-MP) on survival.
Between November 1998 and September 2004, 80 patients from six international transplant centers were entered into the study. Forty patients with a median age of 40 (range, 19-65) years were randomized to receive OKT3 þ HD-MP and another 40 with a median age of 39 (range, 19-56) years to receive single HD-MP. Median time of development of acute GVHD was 11.5 (range, 8-98) days in the OKT3 þ HD-MP and 17 (range, 7-100; P ¼ 0.448) days in the HD-MP group and was not different for patients who had received myeloablative and reduced intensity conditioning respectively. In the HD-MP group, one patient is not evaluable due to an early death without having received any study medication. Both groups were well balanced with respect to gender, sex mismatch (that is, female donor for male recipient), underlying disease, stem cell source and conditioning regimen. However, slightly more patients in the OKT3 þ HD-MP group had received grafts from unrelated donors (mVURD, mmVURD) when compared to the HD-MP group (28 vs 20; P ¼ 0.068). Details are displayed in Table 1 . Thirty patients in the OKT3 þ HD-MP arm (75%) and 29 in the HD-MP group (73%) had grade III/IV disease. With respect to organ systems, significantly more patients in the OKT3 þ HD-MP arm had gut involvement (25 vs 16 patients; P ¼ 0.044), while incidence of skin disease was significantly lower (30 vs 38 patients; P ¼ 0.012). Third-line treatment until day 100 had been initiated in 6 of 34 evaluable subjects (18%) in the antibody group and in 11 of 35 (31%) in the HD-MP arm (P ¼ 0.184). On day 100, overall response rate for OKT3 þ HD-MP treatment was 53% (21 of 40), for steroid only treatment 33% (13 of 39; P ¼ 0.06; Table 2 ). There was a trend for better response in the combination arm for gut GVHD (72 vs 44%; P ¼ 0.070), while objective response rate was not significantly different (56 vs 44%; P ¼ 0.239). With respect to organ involvement on study day 100, treatment with OKT3 was superior increasing response of at least one grade for all organ systems when compared to HD-MP only: absolute increase of response was highest for liver GVHD followed by gut involvement. Thirteen patients (33%) after OKT3 þ HD-MP vs seven (18%) subjects after HD-MP alone were alive without GVHD on day 100 (P ¼ 0.202). Cumulative incidence of bacterial infections was not different between the two groups. Ten of 37 evaluable patients treated with HD-MP (27%) and 4 of 39 subjects (10%) on OKT3 and steroids developed invasive fungal infection (P ¼ 0.059). Viral infections occurred significantly more often in the HD-MP group (28 of 39, 72%) than in the OKT3 þ HD-MP group (14 of 40, 35%; P ¼ 0.001). Diagnosis of invasive fungal infection required positive blood or tissue culture. HHV6 and EBV were only screened for in patients with symptoms possibly related to infections, such as neurologic and CNS symptoms, pneumonia, fever, lymphadenopathy and hepatitis. Twenty-four of 40 patients (60%) who received OKT3 muromonab experienced signs and symptoms of cytokine release syndrome immediately after antibody administration. None of the episodes that included fever, chills, rash, nausea, erythema and skin reactions were of WHO 13/4 toxicity. One patient (3%) developed post-transplant lymphoproliferative disorder that favorably responded to rituximab leading to a CR of the lymphoma. Incidence of hyperglycemia requiring insulin treatment was comparable between the two groups: 17 (43%) and 19 (49%) subjects in the OKT3 þ HD-MP and HD-MP group, respectively, required at least transient insulin. Steroidinduced myopathy occurred in three patients (8%) in each group. Until study day 100, further tapering of steroid doses beyond scheduled reduction until day 8 had been successful in all patients in both groups. Remaining steroid dose for the OKT3 þ HD-MP group was 4.5% (0-17) of initial dose (that is, MP of 10 mg/kg BW or equivalent) and 13.8% (0-25) of initial dose for the patients receiving only corticosteroids, representing a significant difference (Po0.001).
One-year overall survival (OAS), calculated from the day of allogeneic transplant by Kaplan-Meier analysis was one of the secondary end points of the trial and was 45% (18 of 40) for patients who had received OKT3 þ HD-MP vs 36% (14 of 39) for patients treated with HD-MP alone (P ¼ 0.609). Seventeen of 30 patients (57%) vs 9 of 29 subjects (31%) in the OKT3 þ HD-MP and the HD-MP group, respectively, with initial 1III/IV Table 2 Response, survival, adverse effects and causes of death
HD-MP n (%)
Pvalue
Response to therapy at study day 100
Progression (that is, third-line therapy initiated) 3 (8) 1 (2) Abbreviations: CMV, cytomegalovirus; hist. proven, proven by histological examination; NA, not applicable; PTLD, post-transplant lymphoproliferative disorder; SCT, stem cell transplantation; VOD, veno-occlusive disease. Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CML, chronic myelogenous leukemia; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; MP, methylprednisolone; NHL, nonHodgkin's lymphoma; PBSC, peripheral blood stem cells; SCT, stem cell transplantation.
Letters to the Editor GVHD were alive on study day 100 (P ¼ 0.047), while OAS cumulated for all severities had been 59 and 46%, respectively (P ¼ 0.109). Mean OAS was 213 days for the OKT3 þ HD-MP group vs 203 days for the HD-MP group, respectively. For patients responding to treatment, mean OAS was 229 days (antibody recipients) vs 234 days (steroids only; Figure 1 ). Survival was dismal for patients requiring third-line treatment when compared to those having been treated as per protocol: in the OKT3 arm only 1 out of 6, and in the HD-MP arm 1 out of 11 subjects with third-line treatment survived beyond day 100. Regarding patients with severe GVHD (that is, overall severity on day 0 of 1III and 1IV), at 1 year from transplantation 13 of 29 (45%) from the antibody treated patients vs 6 of 28 (21%) subjects who only had received steroids were alive (P ¼ 0.061). Mortality risk was higher at all analyzed time points for patients who had only received steroids. Difference in mortality rates was highest on study day 100 for patients with initial liver involvement. Causes of death were similar in both groups for infectious complications (12 cases each) and for (acute and chronic) GVHD (10 cases each). In the HD-MP group, an additional three patients had died of relapses of their hematological malignancies (vs no relapse mortality in patients having received OKT3) and one of veno-occlusive disease. We additionally analyzed the influence of patient characteristics and treatment parameters on survival in a stepwise logistic regression model: from six variables possibly associated with adverse outcome (infection; treatment arm; age; HLA-disparity; third-line therapy; and sex mismatch between donor and recipient) only older age was associated with higher risk of mortality (P ¼ 0.034). Development of chronic GVHD was not different. This is one of the very few prospective randomized comparisons in steroid refractory acute GVHD. When the current study was set up in 1998, both number and specificity of available salvage therapies were much more limited than it is today. Due to reports that substantial increase in steroid dose (10-20 mg MP per kg BW and day) can result in high remission rates, MP 10 mg/kg BW was favored over ATG for the control arm. 4 Only recently, the Italian group (GITMO) reported on their experience with second-line ATG plus MP 5 mg/kg vs MP 5 mg/kg without finding a difference between the groups. 7 Taking into account also the latter publication, a large number of investigations demonstrated two facts: first, a lack of consensus on the choice of second-line treatment and, second, considerably high mortality rates. 3, 8 We observed a higher overall response rate on study day 100 with OKT3 and high-dose corticosteroids than with steroids alone (53 vs 33%; P ¼ 0.06) despite a higher proportion of patients with a more favorable risk profile in the steroid cohort. Similarly, survival probability of patients with severe GVHD (1III and 1IV) by study day 100 was increased from 31 to 57% and was more than doubled at 1 year from allogeneic transplant (45 vs 21%; P ¼ 0.061) but with small absolute numbers of subjects. Furthermore, a significantly lower incidence of viral infections and a substantial steroid sparing effect was seen in conjunction with the use of OKT3. Probably, better control of acute GVHD by OKT3 allowed a faster and more sustained taper of steroids what subsequently may have lead to a decreased susceptibility to viral pathogens. The short half-life of OKT3 (when compared to ATG) might have been one reason for the rather low risk of severe infectious complications when compared to the steroid only arm of this trial as well as to historical studies with ATG. One could conclude that early T-cell depletion before development of GVHD may be superior to simple suppression of T-cell function by the means of ATG. Mortality rates at 1 year, however, were not different. We conclude that OKT3 in combination with MP 10 mg/kg leads to better control of GVHD and thus directly -and via reduced corticosteroid doses -to a better immune-reconstitution. Subsequently, incidence of opportunistic infections may be reduced. Noteworthy, this did translate into borderline significance for better survival rates for patients with 1III and 1IV acute GVHD who did receive the antibody. Subgroups of patients to whom intensified salvage treatment is beneficial, still need to be more exactly defined. This underscores refractory acute GVHD to remain a problem in recipients of stem-cell allografts that is difficult to manage and warrants further approaches preferably in randomized controlled trials. Kaplan-Meier probability for overall survival in days from allogeneic stem cell transplantation for subjects responding to treatment.
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